Synthetic peptide vaccine confers protection against murine malaria.
Open Access
- 1 November 1987
- journal article
- research article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 166 (5) , 1591-1596
- https://doi.org/10.1084/jem.166.5.1591
Abstract
A synthetic peptide, (DPPPPNPN)2D, representing a subunit of the repeat domain of the Plasmodium berghei circumsporozoite protein, was conjugated to tetanus toxoid using bisdiazobenzidine. Immunization of mice and rats with the conjugate induced high serum titers of antibodies to the parasite, and most of the animals were completely protected from malaria infection when challenged with sporozoites.This publication has 11 references indexed in Scilit:
- Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoitesNature, 1987
- Efficacy of Murine Malaria Sporozoite Vaccines: Implications for Human Vaccine DevelopmentScience, 1987
- Expression in yeast of a Plasmodium vivax antigen of potential use in a human malaria vaccine.The Journal of Experimental Medicine, 1987
- Peptides as antigens. Importance of orientation.The Journal of Experimental Medicine, 1986
- Development of a Sporozoite Malaria VaccineThe American Journal of Tropical Medicine and Hygiene, 1986
- Inhibition of Development of Exoerythrocytic Forms of Malaria Parasites by γ-InterferonScience, 1986
- Infectivity of Plasmodium berghei sporozoites measured with a DNA probeMolecular and Biochemical Parasitology, 1986
- Rationale for Development of a Synthetic Vaccine Against Plasmodium falciparum MalariaScience, 1985
- Antibodies to Sporozoites: Their Frequent Occurrence in Individuals Living in an Area of Hyperendemic MalariaScience, 1979
- tert-Butoxycarbonylaminoacyl-4-(oxymethyl)phenylacetamidomethyl-resin, a more acid-resistant support for solid-phase peptide synthesisJournal of the American Chemical Society, 1976